Evidence map›Paper›PMID 38707818›Full record

ArticleKidney international reports2024

Clinical Presentation, Pathological Spectrum, and Outcomes of Alcoholic Cirrhosis-Related Immunoglobulin A Nephropathy.

Charles Ronsin, Pierre Braud, Christine Kandel-Aznar, Amaury Dujardin, Clémence Petit, David Larmet, Claire Garandeau, Clément Deltombe, Alice Le Clech, Claire Leman and 4 more

Abstract read
In one paragraph

Article in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Charles RonsinDepartment of Nephrology and Immunology, Centre Hospitalier Universitaire de Nantes, Nantes, France.
Pierre BraudDepartment of Nephrology, Dialysis and Transplantation, Departmental Hospital of Vendée, La Roche-sur-Yon, France.
Christine Kandel-AznarDepartment of Pathology, University Hospital, Nantes, France.
Amaury DujardinDepartment of Nephrology, Laval Hospital, Laval, France.
Clémence PetitDepartment of Nephrology, Saint Nazaire Hospital, Saint Nazaire, France.
David LarmetDepartment of Nephrology, Saint Nazaire Hospital, Saint Nazaire, France.
Claire GarandeauDepartment of Nephrology and Immunology, Centre Hospitalier Universitaire de Nantes, Nantes, France.
Clément DeltombeDepartment of Nephrology and Immunology, Centre Hospitalier Universitaire de Nantes, Nantes, France.
Alice Le ClechDepartment of Nephrology and Immunology, Centre Hospitalier Universitaire de Nantes, Nantes, France.
Claire LemanDepartment of Nephrology and Immunology, Centre Hospitalier Universitaire de Nantes, Nantes, France.
Gilles BlanchoDepartment of Nephrology and Immunology, Centre Hospitalier Universitaire de Nantes, Nantes, France.
Juliet SchurderDepartment of Nephrology, Broussais Hospital, Saint-Malo, France.
Grégoire Couvrat-DesvergnesDepartment of Nephrology, Dialysis and Transplantation, Departmental Hospital of Vendée, La Roche-sur-Yon, France.
Simon VilleDepartment of Nephrology and Immunology, Centre Hospitalier Universitaire de Nantes, Nantes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Immunoglobulin A nephropathy (IgAN) associated with cirrhosis is frequent but often overlooked because it is largely considered silent. Until now, little has been known about their presentation and outcomes. Methods: We conducted a retrospective multicenter study on patients with kidney biopsy-proven cirrhosis-related IgAN (cirrhosis-IgAN), diagnosed between 2009 and 2022. We mixed them up with 83 primary IgAN (pIgAN) diagnosed during the same period, using a partitioning clustering approach, to determine common clinicopathological profiles. Results: All the 46 patients with cirrhosis-IgAN had an excessive alcoholic consumption. Clinical presentation was severe with acute kidney injury (AKI) in 79%; alternative causes of AKI was found in 62% of cases. Three clinicopathological clusters were identified as follows: the first one represented chronic involvement, the second one could be assimilated to mild disease, and the third one corresponded to a membranoproliferative glomerulonephritis (MPGN) pattern and was associated with heavy proteinuria and intrinsic AKI (without alternative causes). Whereas the first 2 clusters were equally distributed between pIgAN and cirrhosis-IgAN, the third was more frequent in patients with cirrhosis. The cumulative mortality rate in cirrhosis-IgAN was 26% and 46% at 1-year and 3-years, respectively. Steroid exposure and moderate or severe AKI were associated with higher mortality and steroid exposure was associated with the occurrence of severe infection. Conclusion: Our results suggest that high AKI incidence is related to extrinsic causes in most cases but can also be driven by IgA-dominant MPGN in a subset of patients. Steroid use was associated with infectious disease and mortality. Further studies are needed to clarify the role of immunosuppressive treatment in cirrhosis-IgAN patients.

Indexed as

cirrhosisIgA nephropathyliver disease

Identifiers

PMID38707818
PMCPMC11069013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.